Monitoring of Organ-Transplanted Patients

Cellular Diagnostics: Basic principles, methods and clinical applications of flow cytometry

Volumn , Issue , 2008, Pages 558-579

  Lun, Andreas ^a   Sack, Ulrich ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79956128005     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000209180     Document Type: Chapter

References (87)

1. Eurotransplant. http://www.eurotransplant.nl/index.php?id = statistics. Electronic citation, 2003.
2. Quiroga J, Colina I, Demetris AJ, Starzl TE, Van Thiel DH: Cause and timing of first allograft failure in orthotopic liver transplantation: a study of 177 consecutive patients. Hepatology 1991;14:1054-1062.
3. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH: The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993;56:307-315.
4. Tullius SG, NieminenM, Bechstein WO, Jonas S, Qun Y, Rayes N, et al: Prompt treatment of initial acute rejection episodes may improve long-term graft outcome. Transpl Int 1998;11(suppl 1):S3-S4.
5. Janeway CA, Travers P, Walport M, Shlomchik M: Autoimmunität und Transplantation; in Janeway CA, Travers P, Walport M, Shlomchik M (Hrsg): Immunologie. Heidelberg, Spektrum Akademischer Verlag, 2004, pp 537-591.
6. Sayegh MH, Vella JP: Acute renal allograft rejection: Diagnosis. www.uptodateonline.com, 2004.
7. Vella JP, Sayegh MH: Transplantation immunobiology. www.uptodateonline.com, 2004.
8. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al: Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342-349.
9. Cecka JM: The UNOS Renal Transplant Registry. Clin Transpl 2002;1-20.
10. Nalesnik MA: Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:9-18.
11. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-1821.
12. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, et al: Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998;101:398-405.
13. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, et al: Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997;64:795-800.
14. Watson CJ, Cobbold SP, Davies HF, Rebello PR, Waldmann H, Calne RY, et al: CD4 and CD8 monoclonal antibody therapy in canine renal allografts. Transpl Int 1994;7(suppl 1):S322-S324.
15. Jindal RM, Greer G, Popescu I, Sidner RA: Lymphocyte subset analysis for the diagnosis of rejection and infection in recipients of liver transplants. Am Surg 1999;65:77-80.
16. Döcke WD, Reinke P, Staffa G, Settmacher U, Höger T, Groth J, et al: An immune monitoring program for the management of immunosuppressive therapy in early phase after transplantation. Tex Med 1994;6:13-28.
17. Korom S, De M, I, Onodera K, Stadlbauer TH, Borloo M, Lambeir AM, et al: The effects of CD26/DPP IVtargeted therapy on acute allograft rejection. Transplant Proc 1997;29:1274-1275.
18. Lun A, Cho MY, Muller C, Staffa G, Bechstein WO, Radke C, et al: Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation. Clin Chim Acta 2002; 320:69-78.
19. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RA: Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 1989;47:77-81.
20. Stockenhuber F, Gnant M, Gottsauner-Wolf MT, Apperl A, Steininger R, Sautner T, et al: Soluble interleukin-2 receptor in liver transplant recipients. Transplant Proc 1991;23:1417-1418.
21. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 1994;15:321-331.
22. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
23. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
24. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
25. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG: Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998;161:1659-1663.
26. Baan CC, Boelaars-van Haperen MJ, van Riemsdijk IC, van der Plas AJ, Weimar W: IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies. Transplant Proc 2001;33:2244-2246.
27. Waldmann H, Graca L, Cobbold S, Adams E, Tone M, Tone Y: Regulatory T cells and organ transplantation. Semin Immunol 2004;16:119-126.
28. Banham AH: Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol 2006;27:541-544.
29. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:1701-1711.
30. Hsieh CL, Obara H, Ogura Y, Martinez OM, Krams SM: NK cells and transplantation. Transpl Immunol 2002;9:111-114.
31. Guerra N, Guillard M, Angevin E, Echchakir H, Escudier B, Moretta A, et al: Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 2000;95:2883-2889.
32. Kang N, Guan D, Xing N, Xia C: Expression of CD158b on peripheral blood lymphocytic cell after kidney transplantation. Transplant Proc 2005;37:782-784.
33. Gärtner R, Haen E: Endokrinpharmakologie. In: Forth W, Henschler D, Rummel W, F?rstermann U, Starke K(Hrsg): Allgemeine und spezielle Pharmakologie und Toxikologie. Jena, Urban & Fischer, 2001, pp 671-737.
34. Breidenbach T: Immunsystem/Immunsuppressiva; in Novartis (Hrsg): Handbuch Transplantation - der schnelle Ratgeber. Basel, Novartis, 2004, pp155-175.
35. Kaever V, Resch K: Antiphlogistika und Immuntherapeutika; in Forth W, Henschler D, Rummel W, F?rstermann U, Starke K (Hrsg): Allgemeine und spezielle Pharmakologie und Toxikologie. Jena, Urban & Fischer, 2001, pp 393-427.
36. Waldmann TA, O'Shea J: The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998;10:507-512.
37. Lemmens HP, Langrehr JM, Bechstein WO, Blumhardt G, Keck H, Lusebrink R, et al: Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial. Transplant Proc 1995;27:1140-1141.
38. Lohmann R, Langrehr JM, Klupp J, Neumann U, Guckelberger O, Muller AR, et al: Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. Transplant Proc 1999;31:380.
39. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35(suppl):7S-14S.
40. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, et al: Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000;14:179-188.
41. Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, et al: Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004;7:339-344.
42. Keenan RD, Ainsworth J, Khan N, Bruton R, Cobbold M, Assenmacher M, et al: Purification of cytomegalovirusspecific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001;115:428-434.
43. Crosbie OM, Norris S, Hegarty JE, O'Farrelly C: T lymphocyte subsets and activation status in patients following liver transplantation. Immunol Invest 1998;27:237-241.
44. Herrod HG, Williams J, Dean PJ: Alterations in immunologic measurements in patients experiencing early hepatic allograft rejection. Transplantation 1988;45:923-925.
45. Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, et al: Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994;57:1395-1398.
46. Ninova DI, Wiesner RH, Gores GJ, Harrison JM, Krom RA, Homburger HA: Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol 1994;21:1080-1085.
47. Pross M, Manger T, Weiss G, Lippert H, König w, Kunz D: Die diagnostische Wertigkeit von Procalcitonin und IL-6 in Kombination mit dem zellul ren Immunstatus f?r das therapeutische Management nach Lebertransplantation. Tex Med 1998;10:195-201.
48. Shanahan T: Application of flow cytometry in transplantation medicine. Immunol Invest 1997;26:91-101.
49. Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, et al: Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl 2006;12:277-284.
50. Bestard O, Cruzado JM, Mestre M, Caldes A, Bas J, Carrera M, et al: Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007;179:4901-4909.
51. Reinke P, Fietze E, Docke WD, Kern F, Ewert R, Volk HD: Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells. Transplantation 1994;58:35-41.
52. Lehmann I, Borte M, Sack U. Diagnosis of immunodeficiencies. J Lab Med 2001;25:495-511.
53. Oertel M, Sack U, Kohlhaw K, Lehmann I, Emmrich F, Berr F, et al: Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a longterm study. Transpl Int 2002;15:463-471.
54. Abraham SC, Furth EE: Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995;59:740-746.
55. Tilg H, Vogel W, Aulitzky WE, Herold M, Konigsrainer A, Margreiter R, et al: Evaluation of cytokines and cytokineinduced secondary messages in sera of patients after liver transplantation. Transplantation 1990;49:1074-1080.
56. Hickman PE, Lynch SV, Potter JM, Walker NI, Strong RW, Clouston AD: Gamma glutamyl transferase as a marker of liver transplant rejection. Transplantation 1994;57:1278-1280.
57. Hughes VF, Melvin DG, Niranjan M, Alexander GA, Trull AK: Clinical validation of an artificial neural network trained to identify acute allograft rejection in liver transplant recipients. Liver Transpl 2001;7:496-503.
58. Trull AK, Facey SP, Rees GW, Wight DG, Noble-Jamieson G, Joughin C, et al: Serum alpha-glutathione S-transferase - a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994;58:1345-1351.
59. Azoulay D, Lemoine A, Salvucci M, Adam R, Bismuth H: Prospective evaluation of serum GSTa in a liver transplantation (abstract). Gut 1996;39(suppl 3):A26.
60. Nagral A, Butler P, Sabin CA, Rolles K, Burroughs AK: Alpha-glutathione-S-transferase in acute rejection of liver transplant recipients. Transplantation 1998;65:401-405.
61. Trull AK, Akhlaghi F, Charman SC, Endenberg S, Majid O, Cornelissen J, et al: Immunosuppression, eotaxin and the diagnostic changes in eosinophils that precede early acute heart allograft rejection. Transpl Immunol 2004;12:159-166.
62. Trull AK, Steel LA, Sharples LD, Akhlaghi F, Parameshwar J, Cary N, et al: Randomized trial of blood eosinophil count monitoring as a guide to corticosteroid dosage adjustment after heart transplantation. Transplantation 2000;70:802-809.
63. Nagral A, Ben Ari Z, Dhillon AP, Burroughs AK: Eosinophils in acute cellular rejection in liver allografts. Liver Transpl Surg 1998;4:355-362.
64. Barnes EJ, Abdel-Rehim MM, Goulis Y, Ragab MA, Davies S, Dhillon A, et al: Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation. Am J Transplant 2003;3:432-438.
65. Foster PF, Sankary H, Williams JW: Study of eosinophilia and hepatic dysfunction as a predictor of rejection in human liver transplantation. Transplant Proc 1988;20(suppl 1):676-677.
66. Crosbie OM, Costello PJ, O'Farrelly C, Hegarty JE: Changes in peripheral blood double-negative T-lymphocyte (CD3+ CD4- CD8-) populations associated with acute cellular rejection after liver transplantation. Liver Transpl Surg 1998;4(2):141-145.
67. Lederer SR, Friedrich N, Gruber R, Landgraf R, Toepfer M, Sitter T: Reduced CD40L Expression on ex vivo Activated CD4+ T-Lymphocytes from patients with excellent renal allograft function measured with a rapid whole blood flow cytometry procedure. Int Arch Allergy Immunol 2004;133:276-284.
68. May WS Jr, Cuatrecasas P: Transferrin receptor: its biological significance. J Membr Biol 1985;88:205-215.
69. Minguela A, Garcia-Alonso AM, Marin L, Torio A, Sanchez-Bueno F, Bermejo J, et al: Evidence of CD28 upregulation in peripheral T cells before liver transplant acute rejection. Transplant Proc 1997;29:499-500.
70. Lange H, Muller TF, Ebel H, Kuhlmann U, Grebe SO, Heymanns J, et al: Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int 1999;12:2-9.
71. Martins L, Ventura A, Dias L, Henriques A , Sarmento A, Guimaraes S: Long-term effects of ATG therapy on lymphocyte subsets. Transplant Proc 2001;33:2186-2187.
72. Hartel C, Schumacher N, Fricke L, Ebel B, Kirchner H, Muller-Steinhardt M: Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem 2004;50:141-151.
73. Deng MC, Breithardt G, Scheld HH: The Interdisciplinary Heart Failure and Transplant Program Munster: a 5- year experience. Int J Cardiol 1995;50:7-17.
74. Kootte AM, Henny FC, Tanke HJ, Slats J, van Es LA, Paul LC: Enumeration of Leu2a+, Leu2a+-DR+, and Leu2a+-Leu15+ cells in peripheral blood of renal transplant patients. Transplantation 1988;45:132-138.
75. Rayes N, Bechstein WO, Volk HP, Tullius SG, Nussler N, Naumann U, et al: Distribution of lymphocyte subtypes in liver transplant recipients. Transplant Proc 1997;29:501-502.
76. Rayes N, Bechstein WO, Tullius SG, Nussler NC, Naumann U, Jonas S, et al: Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. Transplant Proc 1998;30:1846-1847.
77. Ganschow R, Broering DC, Nolkemper D, Albani J, Kemper MJ, Rogiers X, et al: Th2 cytokine profile in infants predisposes to improved graft acceptance after liver transplantation. Transplantation 2001;72:929-934.
78. Molajoni ER, Cinti P, Orlandini A, Molajoni J, Tugulea S, Ho E, et al: Mechanism of liver allograft rejection: the indirect recognition pathway. Hum Immunol 1997;53:57-63.
79. Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ: Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004;172:923- 928.
80. Khoury S, Sayegh MH, Turka LA: Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol 1999;18:185-199.
81. Lee RS, Yamada K, Womer KL, Pillsbury EP, Allison KS, Marolewski AE, et al: Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses. J Immunol 2000;164:3434-3444.
82. Li XC, Strom TB. Blocking T-cell costimulation in transplantation: opportunities and challenges. Transfusion 2000;40:139-142.
83. Sawitzki B, Lehmann M, Ritter T, Graser E , Kupiec-Weglinski JW, Volk HD: Regulatory tolerance-mediating T cells in transplantation tolerance. Transplant Proc 2001;33:2092-2093.
84. Reckzeh B, Grebe SO, Rhiele I, Neubauer A , Muller TF: Monitoring of ATG therapy by flow cytometry: comparison of one single-platform and two different dual-platform methods. Transplant Proc 2001;33:2234-2236.
85. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H: Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21:799-803.
86. Meissner N, Kussebi F, Jung T, Ratti H, Baumgarten C, Werfel T et al: A subset of CD8+ T cells from allergic patients produce IL-4 and stimulate IgE production in vitro. Clin Exp Allergy 1997;27:1402-1411.
87. Kaden J, Schutze B, May G: A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients. Transpl Int 1996;9(suppl 1):S63-S67.